^
    13d
    A phase I clinical trial evaluating the effect of food on the pharmacokinetics of TSL-1502, a glucuronide prodrug of a novel oral poly (ADP-ribose) polymerase inhibitor, in healthy Chinese subjects. (PubMed, Front Pharmacol)
    TSL-1502 was well tolerated, and food did not affect its safety profile. These results suggest that TSL-1502 can be administered with or without food.
    P1 data • PK/PD data • Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    TSL1502
    2years
    A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov)
    P2, N=125, Recruiting, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HR positive
    |
    capecitabine • Halaven (eribulin mesylate) • TSL1502
    almost4years
    A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov)
    P2, N=125, Not yet recruiting, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HR positive
    |
    capecitabine • Halaven (eribulin mesylate) • TSL1502